Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults

NCT01857869 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Malaria

Interventions

BIOLOGICAL: GSK257049 Dosage 1
BIOLOGICAL: GSK257049 Dosage 2
PROCEDURE: Sporozoite-infected mosquitoes challenge

Sponsor

GlaxoSmithKline

Collaborators

[object Object]
[object Object]